Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Partnership to take recruitment and development of top-science executives to new level

Abstract:
In response to the growing war for top talent, a unique strategic alliance is announced today between NEXUSBioMed, a highly-specialized boutique executive search firm specializing in the physical and life sciences, and HUMANeX Ventures®, a leading talent-driven consulting, training, coaching, research, and assessment firm.

Partnership to take recruitment and development of top-science executives to new level

Irvine, CA | Posted on August 25th, 2009

The partnership aims to establish long-term, collaborative relationships with companies in the physical and life science industries and provide them with an innovative, integrated approach to talent search, acquisition, and development.

NEXUSBioMed is led by Adriana Petersen, a reputable executive recruiter with more than 25 years of experience and in excess of 3,000 successful placements around the world, and Michael Terlaak, a seasoned entrepreneur with a 20-year track record of successful ventures in a range of industries who leads the company's NEXUSNanoTec division. Brad Black founded HUMANeX Ventures® to combine more than 25 years of his own experience in the development of human capital and building cultures of excellence with the expertise of a team of seasoned "Practitioner Scientists" who have driven scientifically-grounded talent selection practices for organizations across the country.

The two organizations will join forces not only to identify the very best talent for executive-level roles in science-based companies across the country, but also provide clients with measurable data to support the talent identification and selection process through HUMANeX Ventures® scientifically-driven assessment tools. Furthermore, with the development, training, coaching and assessment practices offered by HUMANeX Ventures®, the partnership will provide clients with something that most, if not all other executive search firms cannot: support in the growth and development of human capital AFTER the placement is complete.

"The executive search and recruitment industry is saturated with firms that offer no services beyond recruitment. Similarly, there isn't another talent assessment and development resource that offers the expert-level search capabilities that we can provide through this partnership," said Petersen. "Together, we are unparalleled in our ability to offer top-notch recruitment services supported by scientifically-based assessment practices, not to mention the ongoing partnership with HUMANeX Ventures® to develop an organization's human capital and grow its overall culture."

Petersen added, "This partnership with HUMANeX Ventures® allows us to stand out among other larger firms because we can provide a level of service and expertise that rivals their own menu of services, but with a personal, specialized and more nimble approach that they simply cannot match."

NEXUSBioMed's leadership understands the present and future impact of companies throughout the physical and life sciences, so the partnership between HUMANeX Ventures® and NEXUSBioMed will serve the biomed, pharmaceutical, medical device, healthcare and medical industries. Additionally, in a special effort to support organizations in the rapidly growing nanotechnology industry, NEXUSBioMed has established NEXUSNanoTec. A division of NEXUSBioMed, NEXUSNanoTec specifically addresses the growing need for talent and leadership within the advanced science of nanotechnology. This specialized division partners with start-ups and emerging organizations, as well as those that seed and support them.

Led by NEXUSBioMed co-founder, Michael Terlaak, NEXUSNanoTec is heavily connected and networked within nanotechnology, including professionals in academia, leading scientists, highly-regarded researchers and experts in the private sector. The division will apply the talent acquisition and development processes offered the though NEXUSBioMed and HUMANeX Ventures partnership to support Angel and Seed Investors, venture capitalists, private equity firms, start-ups and emerging companies.

"It is our goal at NEXUSBioMed to build extraordinary teams of talented professionals and leadership that will ensure the success of companies in all the sciences," said Terlaak. "Additionally, through the creation of NEXUSNanoTec, we are extremely well-equipped to help companies involved in nanotechnology grow and help their technologies and products reach the market successfully. We are confident that the best first step in seeing that our clients succeed is by teaming with HUMANeX Ventures to provide objective, scientifically-sound, third-party tools and processes to finding the very best people to lead these growing companies."

The third party assessment process provided by HUMANeX is based on decades of scientific, evidence-based research. The tools and practices used in the selection process ensure the objective, accurate, secure, and measureable identification of specific talents for specific roles within client companies.

"Our assessment tools are founded on qualitative and quantitative data collection, scientific research, and expert analysis," said Black. "We provide the objective, measurable data to both simplify and solidify the executive recruitment process offered by HUMANeX Ventures®. The marriage of our two top models of how to select talent into an organization will bring success to many, many science-based organizations that commit to applying our practices."

HUMANeX Ventures® will also offer clients its integrated services in growing and developing the executive talent they select to join their teams, as well as tools and training to transform their organizations into talent-driven businesses with magnetic workplace cultures of excellence.

"The added value we bring to this partnership, beyond the evidence-based assessment instruments, is our ability to partner with these client organizations to help them take the top performers they select to join their teams and further develop them to reach each individual's potential," said Black. "We don't stop with recruitment of top talent; talent alone isn't enough. You have to develop it and build a culture that nurtures and supports it. You have to create teams of excellence and establish a culture that is committed to excellence and that will attract more top performers who want to be a part of what's happening in your organization. HUMANeX Ventures® has designed a process to help organizations do just that; we're excited to work with NEXUSBioMed to share that process with more leaders and organizations."

In announcing this partnership, NEXUSBioMed and HUMANeX Ventures® are committing to supporting organizations in creation and development of world-class teams that will drive their organizations to new and previously unattainable levels of excellence and success.

Michael Terlaak is the Founder of the Nanotechnology Research Foundation and Adriana Petersen is a Founding Board Member.

####

About NEXUSBioMed
To learn more about NEXUSBioMed, visit www.nexusbiomedresearch.com.

More information about HUMANeX Ventures® can be found on its website, www.humanexventures.com.

For more information, please click here

Contacts:
HUMANeX Ventures
Lindsay Tjepkema
773.459.0408

Copyright © NEXUSBioMed

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024

Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Jobs

Could quantum technology be New Mexico’s next economic boon? Quantum New Mexico Coalition aims to establish state as national hub April 1st, 2022

SEMI Partners with GLOBALFOUNDRIES to Offer Apprenticeship Program Aimed at Building the Electronics Talent Pipeline August 11th, 2020

March 17th, 2020

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 29th, 2019

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Nanobiotechnology

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024

Alliances/Trade associations/Partnerships/Distributorships

Manchester graphene spin-out signs $1billion game-changing deal to help tackle global sustainability challenges: Landmark deal for the commercialisation of graphene April 14th, 2023

Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022

CEA & Partners Present ‘Powerful Step Towards Industrialization’ Of Linear Si Quantum Dot Arrays Using FDSOI Material at VLSI Symposium: Invited paper reports 3-step characterization chain and resulting methodologies and metrics that accelerate learning, provide data on device pe June 17th, 2022

University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project